4-(4-METHOXYPHENYL)-3,5-BIS(CARBOETHOXY)-1,4-DIHYDRO-2,6-DIMETHYLPYRIDINE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QCJJMPZWBYORGR-UHFFFAOYSA-N
Smiles	CCOC(=O)C1=C(C)NC(=C(C1c2ccc(OC)cc2)C(=O)OCC)C
InChI	InChI=1S/C20H25NO5/c1-6-25-19(22)16-12(3)21-13(4)17(20(23)26-7-2)18(16)14-8-10-15(24-5)11-9-14/h8-11,18,21H,6-7H2,1-5H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H25NO5
Molecular Weight	359.42
AlogP	2.55
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	8.0
Polar Surface Area	73.86
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Inhibition of Homo sapiens (human) MRP1 expressed in Sf9 cell membranes assessed as decrease in N-ethyl-maleimide-glutathione-induced inorganic phosphate production at 1 to 1000 uM by spectrophotometric analysis in presence of glutathione	Homo sapiens	None
Cytotoxicity against Homo sapiens (human) HT-29 cells assessed as cell viability after 48 hr by MTT assay	Homo sapiens	None
Cytotoxicity against Homo sapiens (human) MDA-MB cells assessed as cell viability after 48 hr by MTT assay	Homo sapiens	330600.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2063802
PubChem	97201
SureChEMBL	SCHEMBL7814802
ZINC	ZINC17520063

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).